Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.

Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Alan Tan, MD, discusses the 8-year follow-up data from the CheckMate 214 trial of patients with advanced renal cell carcinoma.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Thursday. The brokerage issued a hold rating on the stock. Oncternal ...

If you continue to have this issue please contact [email protected]. Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...